Smallpox LC16m8 vaccine - Kaketsuken

Drug Profile

Smallpox LC16m8 vaccine - Kaketsuken

Alternative Names: LC16m8 smallpox vaccine - Kaketsuken

Latest Information Update: 18 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaketsuken
  • Developer VaxGen
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Smallpox

Most Recent Events

  • 11 Jun 2007 The vaccine is no longer licensed to VaxGen
  • 11 Jun 2007 Discontinued - Phase-I/II for Smallpox in USA (Transdermal)
  • 30 Nov 2005 Preclinical data from a media release have been added to the adverse events and Viral infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top